The DOI matches its Crossref record.
Inhaled Antibiotics for Lower Airway Infections
Open accessAbstract
Inhaled antibiotics have been used to treat chronic airway infections since the 1940s. The earliest experience with inhaled antibiotics involved aerosolizing antibiotics designed for parenteral administration. These formulations caused significant bronchial irritation due to added preservatives and nonphysiologic chemical composition. A major therapeutic advance took place in 1997, when tobramycin designed for inhalation was approved by the U.S. Food and Drug Administration (FDA) for use in patients with cystic fibrosis (CF) with chronic Pseudomonas aeruginosa infection. Attracted by the clinical benefits observed in CF and the availability of dry powder antibiotic formulations, there has been a growing interest in the use of inhaled antibiotics in other lower respiratory tract infections, such as non-CF bronchiectasis, ventilator-associated pneumonia, chronic obstructive pulmonary disease, mycobacterial disease, and in the post–lung transplant setting over the past decade. Antibiotics currently marketed for inhalation include nebulized and dry powder forms of tobramycin and colistin and nebulized aztreonam. Although both the U.S. Food and Drug Administration and European Medicines Agency have approved their use in CF, they have not been approved in other disease areas due to lack of supportive clinical trial evidence. Injectable formulations of gentamicin, tobramycin, amikacin, ceftazidime, and amphotericin are currently nebulized “off-label” to manage non-CF bronchiectasis, drug-resistant nontuberculous mycobacterial infections, ventilator-associated pneumonia, and post-transplant airway infections. Future inhaled antibiotic trials must focus on disease areas outside of CF with sample sizes large enough to evaluate clinically important endpoints such as exacerbations. Extrapolating from CF, the impact of eradicating organisms such as P. aeruginosa in non-CF bronchiectasis should also be evaluated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Shapiro, A. J., Zariwala, M. A., Ferkol, T., Davis, S. D., Sagel, S. D., Dell, S. D., Rosenfeld, M., Olivier, K. N., Milla, C., Daniel, S. J., et al. (2016) · Pediatric Pulmonology · doi:10.1002/ppul.23304 · Cited by 457
Management of bronchiectasis in adults
Chalmers, J. D., Aliberti, S., & Blasi, F. (2015) · European Respiratory Journal · doi:10.1183/09031936.00119114 · Cited by 286
Amikacin: Uses, Resistance, and Prospects for Inhibition
Ramirez, M., & Tolmasky, M. (2017) · Molecules · doi:10.3390/molecules22122267 · Cited by 265
McGill, J. B., Peters, A., Buse, J. B., Steiner, S., Tran, T., Pompilio, F. M., & Kendall, D. M. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00958-8 · Cited by 35
Metadata
- Authors
- Quon, B. S., Goss, C. H., & Ramsey, B. W.
- Venue
- Annals of the American Thoracic Society
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-03-01
- Volume
- 11
- Issue
- 3
- Pages
- 425-434
- ISSN
- 2325-6621 (ISSN-L)
- 2329-6933
- OpenAlex
- W2153220508
- Cited by
- 207
- References
- 0
- FWCI
- 14.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhaled Antibiotics for Lower Airway Infections. https://app.cochat.ai/papers/10.1513/annalsats.201311-395fr
- The paper
- Quon, B. S., Goss, C. H., & Ramsey, B. W. (2014). Inhaled Antibiotics for Lower Airway Infections. Annals of the American Thoracic Society. https://doi.org/10.1513/annalsats.201311-395fr
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.